Compare Heron Therapeutics Inc (HRTX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs United States Natural Gas Fund — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while United States Natural Gas Fund trades at $10.92 (market cap $517.27M). The key difference: United States Natural Gas Fund is far larger — about 7.6× Heron Therapeutics Inc's market cap, and United States Natural Gas Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and United States Natural Gas Fund for 22 Days on average.
| HRTX | UNG | |
|---|---|---|
Market Cap | $68.01M | $517.27M |
Volume | 1,891,941 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $1.49 | $16.90 |
52-Week Low | $0.27 | $9.63 |
Typical Hold Time | 35 Days | 22 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net income of $65.15 million in 2024 with no revenue, while cash flow from operations was positive at $47.54 million. Recent news highlights natural gas price volatility driven by record U.S. production and geopolitical tensions in the Middle East.
The outlook is mixed: strong profitability and low debt support fundamentals, but zero revenue and negative net cash flow pose risks. Geopolitical events and weather-dependent demand create volatility, making the stock sensitive to energy market shifts. Analyst sentiment is cautiously optimistic given the bullish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
